Ampio Pharmaceuticals names new chief financial officer
11 July 2019 -

Ampio Pharmaceuticals Inc (NYSE American: AMPE), a development stage biopharmaceutical company, announced yesterday that it has named Dan Stokely as its new chief financial officer.

Stokely has more than 30 years of experience in finance and accounting and is a Certified Public Accountant. He started his career at Deloitte & Touche and since that time, he has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Most recently, since 2012, he served as executive vice president and chief financial officer of Sentynl Therapeutics, a privately-held specialty pharmaceutical company focused on in-licensing, acquisition, marketing and distribution of development stage and commercially marketed prescription products, which was sold to Cadila Healthcare Ltd in January 2017. From 2004 to 2012, Stokely served as vice president of Finance and chief accounting officer of Victory Pharma, a privately-held specialty pharmaceutical company focused on in-licensing, internal product development, marketing and distribution of pain specialty products, which was sold to Shionogi Inc, a Japanese pharmaceutical company, in 2011. From 2001 to 2004, Stokely served as the corporate controller and chief accounting officer for Wireless Facilities Inc. (currently Kratos Defense & Security Solutions), a publicly traded, global provider of communications and security services for the wireless communications industry. From 1994 to 2001, he served as corporate controller for Dura Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Elan Pharmaceuticals in late 2000. Stokely has a bachelor's degree in accounting from San Diego State University.